Yu Liu

Yu Liu

Auto-generated profile, based on publicly available information

Yu Liu

Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenetics, Changsha, Hunan, PR China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2013 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
YLYu Liu
Yu Liu
HYHeng Yin
Heng Yin
MZMing Zhao
Ming Zhao
QLQianjin Lu
Qianjin Lu

1 September 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
YLYu Liu
Yu Liu
JWJiayu Wang
Jiayu Wang
SLShuangyan Luo
Shuangyan Luo
YZYi Zhan
Yi Zhan
QLQianjin Lu
Qianjin Lu

1 August 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
XLXiao Liu
Xiao Liu
WZWei Zhang
Wei Zhang
MZMing Zhao
Ming Zhao
LFLongfei Fu
Longfei Fu
LLLimin Liu
Limin Liu
QLQianjin Lu
Qianjin Lu
Objective T cell receptor (TCR) diversity determines the autoimmune responses in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and is closely associated with autoimmune diseases prognosis and prevention. However, the characteristics of variations in TCR diversity and their clinical significance is still unknown. Large series of patients must be studied in order to elucidate the effects of these variations. Methods Peripheral blood from 877 SLE patients, 206 RA patients and 439 healthy controls (HC) were amplified for the TCR repertoire and sequenced using a high-throughput sequencer. We have developed a statistical model to identify disease-associated TCR clones and diagnose autoimmune diseases. Results Significant differences were identified in variable (V), joining (J) and V-J pairing between the SLE or RA and HC groups. These differences can be utilised to discriminate the three groups with perfect accuracy (V: area under receiver operating curve > 0.99). One hundred ninety-eight SLE-associated and 53 RA-associated TCRs were identified and used for diseases classification by cross validation with high specificity and sensitivity. Disease-associated clones showed common features and high similarity between both autoimmune diseases. SLE displayed higher TCR heterogeneity than RA with several organ specific properties. Furthermore, the association between clonal expansion and the concentration of disease-associated clones with disease severity were identified, and pathogen-related TCRs were enriched in both diseases. Conclusions These characteristics of the TCR repertoire, particularly the disease-associated clones, can potentially serve as biomarkers and provide novel insights for disease status and therapeutical targets in autoimmune diseases.

14 March 2015 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
SLShuangyan Luo
Shuangyan Luo
YLYu Liu
Yu Liu
GLGongping Liang
Gongping Liang
MZMing Zhao
Ming Zhao
HWHaijing Wu
Haijing Wu
QLQianjin Lu
Qianjin Lu
The pathogenesis of systemic lupus erythematosus (SLE) has not yet been completely elucidated. One of the hallmarks of SLE is the production of autoantibodies by uncontrolled over-activated B cells. Early B cell factor 1 (EBF1) contributes to the development, activation, and proliferation of B cells through activation of the AKT signaling pathway. Accumulating evidence has demonstrated that several microRNAs (miRNAs) contribute to the pathogenesis of autoimmune diseases through the regulation of B cells in SLE. We aim to investigate the expression patterns of miR-1246 in B cells and its contribution to pathogenesis of SLE. Our results showed that the expression of miR-1246 was significantly decreased in B cells from SLE patients. We verified that miR-1246 specifically targeted the EBF1 messenger RNA (mRNA) by interacting with its 3′-untranslated region (3′-UTR) and regulated the expression of EBF1. Transfection of miR-1246 inhibitors into healthy B cells upregulated the expression of EBF1, enhanced B cell function, and increased the production of B cell surface co-stimulatory molecules CD40, CD80, and CD86. We also observed that abnormal activation of the AKT signaling pathway was associated with decreased P53 expression, leading to the downregulation of the miR-1246 expression; and upregulation of the miR-1246 expression reversed the responsiveness of B cells by inhibiting EBF1 expression. Activated B cells in lupus could decrease the expression of miR-1246 through the AKT-P53 signaling pathway, which in turn enhances the expression of EBF1, thereby promoting further activation of B cells. Conversely, upregulation of miR-1246 could interrupt this amplification pathway. Our findings thus provide a theoretical framework towards the research of novel biological targets in SLE treatment.

15 June 2015 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
YLYu Liu
Yu Liu
JLJieyue Liao
Jieyue Liao
MZMing Zhao
Ming Zhao
HWHaijing Wu
Haijing Wu
SYSusan Yung
Susan Yung
QLQianjin Lu
Qianjin Lu
The innate immune system has been shown to play an important pathologic role in systemic lupus erythematosus (SLE). TLR2, a PRR, recognizes exogenous PAMPs, and endogenous damage‐associated molecular patterns and has been implicated in the initiation and maintenance of the perpetuated inflammatory reactions in autoimmune diseases. Here, we report increased expression of TLR2 in CD4+ and CD8+ T cells, CD19+ B cells, and CD14+ monocytes from SLE patients. Conventional treatment, such as hydroxychloroquine and corticosteroids, showed no effect on TLR2 expression in CD4+ T cells from SLE patients. In vitro stimulation of TLR2 in CD4+ T cells from SLE patients increased CD40L and CD70 expression, as well as secretion of IL‐6, IL‐17A, IL‐17F, and TNF‐α, while Foxp3 transcription decreased. This effect was reversed by TLR2 siRNA. Moreover, TLR2 activation upregulated H3K4 tri‐methylation and H4 acetylation levels while downregulated H3K9 tri‐methylation level in the IL‐17A promoter region. In addition, it also increased H4 acetylation levels and decreased H3K9 tri‐methylation levels in the IL‐17F promoter region. In summary, our findings demonstrate that increased expression of TLR2 contributes to immune reactivity and promotes IL‐17A and IL‐17F expression through histone modifications in SLE.

19 November 2013 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
YLYu Liu
Yu Liu
HLHui Li
Hui Li
TXTao Xiao
Tao Xiao
QLQianjin Lu
Qianjin Lu